PP_1170x120_10-25-21

BD

BD acquires MedKeeper to offer cloud-based, connected pharmacy software

BD acquires MedKeeper to offer cloud-based, connected pharmacy software

FRANKLIN LAKES, N.J. – BD (Becton, Dickinson and Co.) announced on Thursday it has acquired MedKeeper, a provider of modern, cloud-based pharmacy management applications. MedKeeper strategically complements BD’s existing presence in the pharmacy – where the company has pioneered solutions in compounding, logistics workflow, controlled substance management and inventory optimization. MedKeeper’s platform will become part of

Clinical pharmacist-led patient care improves health measures in low-income patients

Clinical pharmacist-led patient care improves health measures in low-income patients

FRANKLIN LAKES, N.J. — Recent research published in the Journal of the American College of Clinical Pharmacy shows that investments made in clinical pharmacist-led patient care can substantially improve health measures in low-income patients facing a debilitating chronic disease. The paper, titled The impact of clinical pharmacist-led comprehensive medication management on diabetes care at Federally Qualified Health

BD completes acquisition of Parata Systems

BD completes acquisition of Parata Systems

FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Co.) announced on Monday that it has completed the acquisition of Parata Systems. Parata advances BD’s transformative solutions strategy by providing a portfolio of innovative pharmacy automation solutions that power a growing network of pharmacies to reduce costs, enhance patient safety and improve the patient experience for

BD and Mitsubishi team

BD and Mitsubishi team

FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Co.) and Mitsubishi Gas Chemical Company (MGC), a R&D-oriented chemical manufacturer based in Tokyo, Japan,  announced Wednesday that they have entered into an agreement to investigate further development of OXYCAPT – an innovation from MGC that integrates the best of plastic and glass for plastic syringes. Together,

BD to showcase commitment to drug delivery excellence at Pharmapack 2022

BD to showcase commitment to drug delivery excellence at Pharmapack 2022

FRANKLIN LAKES, N.J. — BD is now a Premium Partner at Pharmapack 2022 – the European hub for the pharma packaging and drug delivery device industry – which will take place on May 18-19, 2022 at Paris Expo, Porte de Versailles, in Paris, France. The return to in-person meetings provides us with the opportunity to

BD launches BD UltraSafe Plus 2.25 mL Passive Needle Guard

BD launches BD UltraSafe Plus 2.25 mL Passive Needle Guard

FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Co.) announced the launch of the BD UltraSafe Plus 2.25 mL Passive Needle Guard for use by pharmaceutical companies in drug-device combination products.  When combined with a Glass Prefillable Syringe, the BD UltraSafe Plus 2.25 mL system enables the subcutaneous delivery of biologic solutions of different fill

BD unveils manufacturing capacity to support U.S. vaccination agility and preparedness

BD unveils manufacturing capacity to support U.S. vaccination agility and preparedness

FRANKLIN LAKES, N.J. – BD (Becton, Dickinson and Company) has strengthened the U.S. government’s access to safety injection devices through increased manufacturing capacity and domestic supply. The new syringe and needle manufacturing lines, which were completed on an accelerated timeline, represent the public-private partnership between BD and Department of Health and Human Services’ (HHS) Assistant

BD completes study investigating performance of glass PFS in deep cold storage

BD completes study investigating performance of glass PFS in deep cold storage

FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Co.) recently completed a preliminary study investigating the impact of deep cold storage (-20°C and -40°C) on glass PFS. While traditional vaccine formulations are commonly stored up to about 2°C-8°C, new vaccine formulations – including those for mRNA – require much colder storage for over a long

BD gets EUA for first at-home COVID-19 test to use smartphone to interpret, deliver results

BD gets EUA for first at-home COVID-19 test to use smartphone to interpret, deliver results

FRANKLIN LAKES, N.J. —  BD (Becton, Dickinson and Co.) announced this week the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the BD Veritor At-Home COVID-19 Test — the first at-home COVID-19 rapid antigen test to use computer vision technology in a smartphone to interpret and provide a digital

BD, CerTest Biotec announce CE mark for molecular test to detect, identify certain SARS-CoV-2 variants

BD, CerTest Biotec announce CE mark for molecular test to detect, identify certain SARS-CoV-2 variants

FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Co.) and CerTest Biotec, announced on Friday the CE mark for a molecular test that can detect and distinguish between the Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) SARS-CoV-2 variants. VIASURE SARS-CoV-2 Variant Real Time PCR Detection Kit for BD MAX can be used as a combined test

BD to build high tech manufacturing facility in Zaragoza, Spain

BD to build high tech manufacturing facility in Zaragoza, Spain

MADRID, Spain — BD (Becton, Dickinson and Company) announced that it will build a €165 million ($200 million USD) high-tech manufacturing facility in city of Zaragoza, located in the Aragon region of Spain, that will create up to 600 jobs by 2030. BD plans to begin construction of the new plant in late 2021, and the

BD announces assay for identification of COVID-19 patients

BD announces assay for identification of COVID-19 patients

EYSINS, Switzerland — BD (Becton, Dickinson and Co.) announced the CE mark of BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes with expanded clinical application to help clinicians identify COVID-19 patients at increased relative risk of intubation with mechanical ventilation (IMV) and  mortality at hospital admission, in conjunction with clinical findings and the results of other laboratory testing. By

New clinical trial data demonstrates BD Libertas Wearable Injector as a drug delivery system

New clinical trial data demonstrates BD Libertas Wearable Injector as a drug delivery system

FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Co.) announced on Wednesday the publication of the results from a 52-subject human clinical trial with the BD Libertas Wearable Injector. The subcutaneous drug delivery system, currently in final phases of development, is designed as ready to use and to deliver drugs such as biologics with viscosities

Adheris Health